Clinical Trials Browser

Not yet recruiting × Tacrolimus × 1 year × Clear all

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT07524530 2026-04-17

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Phase 2 Not yet recruiting

98 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Hematologic Neoplasms

NCT07349771 2026-04-16

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

Phase 2 Not yet recruiting

72 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT06084780 2026-04-09

TRANSCAPE

Phase 2 Not yet recruiting

20 enrolled

Pseudomyxoma Peritonei

NCT06996119 2025-05-30

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Phase 1 Not yet recruiting

15 enrolled

MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Clinical Trials

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

TRANSCAPE

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant